Publication | Closed Access
Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide
32
Citations
27
References
2017
Year
The exposure-adjusted incidence rate of acute pancreatitis in dulaglutide-treated patients was similar to the rates with placebo, with few reported cases during the entire program.
| Year | Citations | |
|---|---|---|
Page 1
Page 1